Article

Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review

Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Gastroenterology (Impact Factor: 13.93). 01/2012; 142(1):46-54.e42; quiz e30. DOI: 10.1053/j.gastro.2011.10.001
Source: PubMed

ABSTRACT We conducted a systematic review to determine changes in the worldwide incidence and prevalence of ulcerative colitis (UC) and Crohn's disease (CD) in different regions and with time.
We performed a systematic literature search of MEDLINE (1950-2010; 8103 citations) and EMBASE (1980-2010; 4975 citations) to identify studies that were population based, included data that could be used to calculate incidence and prevalence, and reported separate data on UC and/or CD in full manuscripts (n = 260). We evaluated data from 167 studies from Europe (1930-2008), 52 studies from Asia and the Middle East (1950-2008), and 27 studies from North America (1920-2004). Maps were used to present worldwide differences in the incidence and prevalence of inflammatory bowel diseases (IBDs); time trends were determined using joinpoint regression.
The highest annual incidence of UC was 24.3 per 100,000 person-years in Europe, 6.3 per 100,000 person-years in Asia and the Middle East, and 19.2 per 100,000 person-years in North America. The highest annual incidence of CD was 12.7 per 100,000 person-years in Europe, 5.0 person-years in Asia and the Middle East, and 20.2 per 100,000 person-years in North America. The highest reported prevalence values for IBD were in Europe (UC, 505 per 100,000 persons; CD, 322 per 100,000 persons) and North America (UC, 249 per 100,000 persons; CD, 319 per 100,000 persons). In time-trend analyses, 75% of CD studies and 60% of UC studies had an increasing incidence of statistical significance (P < .05).
Although there are few epidemiologic data from developing countries, the incidence and prevalence of IBD are increasing with time and in different regions around the world, indicating its emergence as a global disease.

3 Followers
 · 
316 Views
  • Source
    • "These proteins cause damage to the small intestine of patients with CD which results in malabsorption of nutrients (McGough, 2005; Thompson, 1997). The incidence of CD is approximately 1% in both the United States and Europe (Molodecky et al., 2012; Rubio-Tapia, Ludvigsson, Brantner, Murray, & Everhart, 2012). The disease is of considerable interest in those countries in which the offending cereals are consumed. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Enriched caricain was able to detoxify a major proportion of the gliadin in wholemeal wheat dough by allowing it to react for 5 h at 37°C during the fermentation stage. A reduction of 82 % in toxicity, as determined by the rat – liver lysosome assay, was achieved using 0.03 % enzyme on weight of dough. Without enzyme, only 26 % reduction occurred. The difference in reduction of toxicity achieved is statistically significant (p < 0.01). The results are very similar to those obtained in our previous work using an immuno assay and the same enzyme preparation. They confirm the value of caricain as a means of reducing the toxicity of gliadin and open the way for enzyme therapy as an adjunct to the gluten free diet. This approach should lead to better control over the elimination of dietary gluten intake in conditions such as coeliac disease and dermatitis herpetiformis.
    Food Chemistry 07/2015; DOI:10.1016/j.foodchem.2015.07.105 · 3.26 Impact Factor
  • Source
    • "Crohn's disease is an inflammatory bowel disease that occurs in any part of the human gastrointestinal tract and that can cause inflammation in various parts of the body. The disease was characterized as an autoimmune disease with a prevalence of 322 per 100,000 persons [1]. Crohn's disease is a complex disease that is influenced by both environmental factors and the genetic disposition of the host. "
  • Source
    • "Although the frequency of IBD is increasing worldwide , its etiology is still not fully elucidated [1] [2] [3] [4] [5]. Previous studies have suggested several potential mechanisms including genetic predisposition, environmental factors and dysregulated immune response. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The prevalence of inflammatory bowel disease (IBD) is increasing. Since patients usually need long-term treatment and suffer from reduced quality of life, there is a need to develop new therapeutic strategy. The aim of this study was to investigate the therapeutic potential of erythropoietin (EPO) for the treatment of IBD. Murine colitis was induced by 3.0% Dextran Sulfate Sodium (DSS). Recombinant human EPO (rhEPO) was given to evaluate the anti-inflammatory and regenerative effects on intestinal inflammation. The effect of rhEPO on human colon epithelial cells was also evaluated. Immunohistochemical analysis of EPO receptor was performed in human IBD tissues. While about 62% of control mice with severe colitis induced by 5-day DSS died, 85% of mice treated with rhEPO survived. Histological analysis confirmed that EPO treatment reduced the colonic inflammation. Furthermore, EPO treatment significantly downregulated the local expressions of IFN-γ, TNF-α and E-selectin in the colon, suggesting that the effect was associated with inhibiting local immune activation. In a 4-day DSS-induced colitis model, rhEPO significantly improved the recovery of body weight loss compared to controls. Furthermore, proliferating cell nuclear antigen expression was significantly upregulated in the colon tissue from mice treated with rhEPO compared to controls. In addition, rhEPO increased the growth of cultured human colon epithelial cells in a dose-dependent manner. Furthermore, EPO-receptor expression was confirmed in human IBD colon tissues. Three major functions of EPO, hematopoiesis, anti-inflammation and regeneration, may produce significant effects on intestinal inflammation, therefore suggesting that rhEPO might be useful for IBD.
    Scandinavian Journal of Gastroenterology 04/2015; 50(9):1-9. DOI:10.3109/00365521.2015.1020861 · 2.33 Impact Factor
Show more